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ABSTRACT
Background. The multi-institutional registry in this study
evaluated the outcome after cytoreductive surgery (CRS)
plus hyperthermic intraperitoneal chemotherapy (HIPEC)
for patients with peritoneal metastases (PM) from small
bowel adenocarcinoma (SBA).
Methods. A multi-institutional data registry including 152
patients with PM from SBA was established. The primary
end point was overall survival (OS) after CRS plus HIPEC.
Results. Between 1989 and 2016, 152 patients from 21
institutions received a treatment of CRS plus HIPEC. The
median follow-up period was 20 months (range
1–100 months). Of the 152 patients, 70 (46.1%) were
women with a median age of 54 years. The median peri-
toneal cancer index (PCI) was 10 (mean 12; range 1–33).
Completeness of cytoreduction (CCR) 0 or 1 was achieved
for 134 patients (88.2%). After CRS and HIPEC, the median
OS was 32 months (range 1–100 months), with survival
rates of 83.2% at 1 year, 46.4% at 3 years, and 30.8% at
5 years. The median disease-free survival after CCR 0/1 was
14 months (range 1–100 months). The treatment-related
mortality rate was 2%, and 29 patients (19.1%) experienced
grades 3 or 4 operative complications. The period between
detection of PM and CRS plus HIPEC was 6 months or less
(P = 0.008), and multivariate analysis identified absence of
lymph node metastasis (P = 0.037), well-differentiated
tumor (P = 0.028), and PCI of 15 or lower (P = 0.003) as
independently associated with improved OS.
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Conclusion. The combined treatment strategy of CRS plus
HIPEC achieved prolonged survival for selected patients
who had PM from SBA with acceptable morbidity and
mortality.
Small bowel cancer is a rare malignancy comprising less
than 5% of all gastrointestinal cancers.1 In the United
States, about 9410 patients received a new diagnosis of
small bowel cancer in 2015.2 Adenocarcinoma is a frequent
subtype, accounting for 37% of all small bowel cancers.1
Clinicians find it challenging to detect small bowel ade-
nocarcinoma (SBA) in early stages of cancer due to vague
or even absent symptoms and lack of a screening exami-
nation. Therefore, SBA typically presents as advanced
disease.3
Surgical resection remains the mainstay of treatment
strategy for patients with SBA. However, the prognosis of
patients with SBA is poor, with a 5-year survival rate of
15–33% and a median overall survival (OS) ranging from
12 to 20 months.1,3–5
Peritoneal metastases (PM) and hepatic metastases are
the most common failure patterns for SBA.4 The current
standard treatment for patients with advanced SBA is
systemic chemotherapy, with regimens typically extrapo-
lated from those for colorectal cancer.5 In a prospective
phase 2 study, advanced SBA patients who received
chemotherapy including capecitabine and oxaliplatin had a
median OS of 20.4 months.6 In two multicenter retro-
spective studies reported by Zaanan et al.7 and Tsushima
et al.8 advanced SBA patients who received chemotherapy
using FOLFOX and fluoropyrimidine-oxaliplatin had OS
periods of 17.8 months and 22.2 months, respectively,
which were significantly better than the OS for patients
who received other chemotherapy regimens. As a result,
fluoropyrimidine-oxaliplatin is now considered as a first-
line chemotherapy regimen for advanced SBA. However, a
consensus on the treatment for SBA patients with PM has
not been reached.
Cytoreductive surgery (CRS) plus hyperthermic
intraperitoneal chemotherapy (HIPEC) has been widely
applied in the treatment of PM from various origins such as
colorectal cancer, malignant peritoneal mesothelioma, and
pseudomyxoma peritonei.9–11 Moreover, the survival ben-
efit for selected patients has been proved. Several
retrospective single-institution studies evaluating CRS plus
HIPEC in the treatment of PM from SBA have been
reported.12–18 In general, the patient numbers in these
studies are very low, prohibiting adequate analysis of
efficacy and safety.
Therefore, in an effort to collect sufficient data to
evaluate CRS plus HIPEC for patients with PM from SBA,
a multi-institutional study was performed including all
consecutive cases in participating centers.
METHODS
A multi-institutional data registry on PM from SBA
treated by CRS plus HIPEC was established during the 9th
International Congress on Peritoneal Surface Malignancy
at Amsterdam, the Netherlands, in October 2014. Ethics
approval was obtained from the participating institutions
through their institutional review boards or through the
chairpersons of their ethics committees.
The inclusion criteria specified histologic confirmation
of PM from SBA and reception of treatment involving CRS
plus HIPEC. The exclusion criteria ruled out patients with
PM from small bowel cancer with a histology of carcinoid,
lymphoma, gastrointestinal stromal tumors, and sarcoma as
well as patients who did not receive treatment of CRS plus
HIPEC.
The patients were treated with CRS including the peri-
tonectomy procedures as indicated by Sugarbaker.19
During the surgery, the extent of PM via the peritoneal
cancer index (PCI) was evaluated detail.20
After CRS, HIPEC was administered using an open
coliseum procedure or closed technique, depending on the
individual unit’s preference, with chemotherapy agents in
heated solution. The extent of CRS was determined by
completeness of cytoreduction (CCR) according to the
criteria described by Surgarbaker.20 Adverse events
occurring during the 3 months after surgery were graded
according to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events, version 3.0.21
A standard data form was created to retrieve relevant
information on the course of patients with PM from SBA
treated by CRS plus HIPEC. Clinicopathologic and treat-
ment-related variables were included in the subsequent
data analysis to identify prognostic factors because they
possibly held potential clinical implications for future
patient management.
Statistical Analysis
Overall survival after CRS plus HIPEC was calculated
from the date of CRS plus HIPEC to the patient’s death or
the latest follow-up visit. The primary end point of this
study was the OS after CRS plus HIPEC. The secondary
end points were identification of the clinicopathologic and
treatment-related prognostic factors for OS and evaluation
of the safety of CRS plus HIPEC.
Disease-free survival (DFS) was calculated from the
date of CRS plus HIPEC to the date of recurrence detected
in patients who received complete cytoreduction of CCR
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0/1. Survival analysis was performed using the Kaplan–
Meier method and compared using the log-rank test and a
Cox proportional hazards regression model using variables
with significant P values from the univariate analysis for
the multivariate analysis. All statistical analyses were
performed with the Statistical Package for Social Sciences,
version 17.0 (IBM, Armonk, NY, USA), and P values
lower than 0.05 were considered to be statistically
significant.
RESULTS
Clinicopathologic Data
Between 1989 and 2016, 152 patients from 21 institu-
tions (17 from Western countries, 4 from Asia) with PM
from SBA received a treatment of CRS plus HIPEC. The
clinicopathologic characteristics of the patients are listed in
Table 1. Of the 152 patients, 70 (46.1%) were women and
82 (53.9%) were men with a median age of 54 years (mean
52.5 ± 11.0 years; range 30–77 years).
For 123 (81%) of the patients, primary tumor resection
was performed before CRS and HIPEC, and for 82 of the
patients, systemic chemotherapy was administered between
detection of PM and CRS plus HIPEC. The main regimens
of preoperative systemic chemotherapy were FOLFOX,
FOLFIRI, XELOX, and TS-1. Adjuvant chemotherapy was
administered to 81 patients after CRS plus HIPEC. Simi-
larly, FOLFOX, FOLFIRI, and TS-1 were the main
adjuvant chemotherapy regimens in this study.
For 51 patients with metachronous PM (33.6%), the
median interval between primary surgery and detection of
PM was 13 months (mean 17 ± 16.8 months; range
1–70 months). The histology of 10 patients showed a
component of mucinous adenocarcinoma. The median
interval between detection of PM and CRS plus HIPEC
was 5 months (mean 7.4 ± 9.5 months; range
0–60 months). Of 13 patients (8.6%) with extraperitoneal
metastasis besides PM, 12 had liver metastasis. The
remaining patient had lung metastasis. The median PCI
found at CRS and HIPEC was 10 (mean 12; range 1–33).
Treatment-Related Data
In this study, CCR 0 and 1 were achieved respectively
for 114 (75%) and 20 (13.2%) patients. Total parietal
peritonectomy, defined as peritonectomy performed in
areas including both sides of the anterior abdominal wall as
well as the subphrenic area, paracolic gutter, Morison’s
pouch, and pelvis, was performed for 46 patients (30.3%),
and partial peritonectomy was performed for 78 patients
(51.3%). The surgical resections included omentectomy
(n = 117), small bowel (n = 132), colon and/or rectum
(n = 101), cholecystectomy (n = 65), splenectomy
(n = 62), appendectomy (n = 71), hysterectomy (n = 35),
oophorectomy (n = 36), partial hepatectomy (n = 15),
gastrectomy (n = 6), partial pancreatectomy (n = 7), and
partial cystectomy (n = 4).
All 152 patients (100%) underwent HIPEC. The
chemotherapy regimens used for HIPEC are summarized in
Table 2, with 13 institutions using a coliseum (open) pro-
cedure, and 8 units using a closed technique. The duration
of HIPEC was 30 to 120 min (median, 60 min), and the
intraperitoneal temperature was 41–43 C (median 42 C).
For 12 patients (7.9%), early postoperative chemotherapy
(EPIC) was performed after surgery. The mean duration of
CRS plus HIPEC was 380 min (median 360 min; range
60–805 min). The mean volume of blood loss was 0.750 L
(median 0.500 L; range 0.020–5.850 L). The mean volume
of red blood cell (RBC) transfusion was 2 units (range
0–16 units), with 92 patients receiving no transfusion of
RBC. The mean transfusion of fresh frozen plasma (FFP)
was 2.5 units (range 0–18 units), with 90 patients receiving
no transfusion of FFP. The mean hospital stay was 19 days
(median 16 days; range 5–84 days). A repeat CRS plus
HIPEC was performed for 18 patients (11.8%) after tumor
recurrence was detected.
The mortality rate was 2%, with one patient dying due to
multiple organ failure 35 days after surgery, one patient
dying due to disseminated intravascular coagulation
49 days after surgery, and one patient dying due to pul-
monary failure 84 days after surgery.
The overall morbidity rate was 39.5% (7 unknown
cases), with 29 patients (19.1%) experiencing major com-
plications of grade 3 or 4. For 10 patients (6.6%), a
reoperation was needed after CRS plus HIPEC. The major
complications were intraperitoneal abscess (n = 8), pleural
effusion (n = 5), septicemia (n = 7), intestinal fistula
(n = 7), hemorrhage (n = 6), neutropenia (n = 4), ileus
(n = 4), gastrointestinal bleeding (n = 2), wound dehis-
cence (n = 3), and urinary bladder fistula (n = 2).
Survival Outcome
For all 152 patients who received CRS plus HIPEC, the
median follow-up period was 20 months (range
1–100 months). The median OS after CRS plus HIPEC was
32 months (range 1–100 months). After CRS plus HIPEC,
the survival rate was 83.2% at 1 year, 46.4% at 3 years,
and 30.8% at 5 years (Fig. 1). The median DFS after CRS
plus HIPEC for patients who received CCR 0 or 1 was
14 months (range 1–100 months) (Fig. 2). Until the last
follow-up visit, 47 patients were alive without evidence of
disease, and 26 patients were alive with disease.
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Univariate analysis identified the following 13 signifi-
cant prognostic variables associated with improved
survival after CRS plus HIPEC: resection of primary tumor
before CRS plus HIPEC (P = 0.045), interval of 6 months
or less between detection of PM and CRS plus HIPEC
(P = 0.008), well-differentiated tumor (P = 0.037),
absence of lymph node metastasis during CRS plus HIPEC
(P\ 0.0001), absence of extraperitoneal metastasis
(P = 0.030), normal value of CA 125 (P = 0.028), normal
value of CA 19-9 (P = 0.008), absence of ascites
(P = 0.022), PCI of 15 or lower (P\ 0.0001), CCR of 0
(P\ 0.0001), oxaliplatin-based regimen of HIPEC
(P = 0.038), absence of postoperative complications
(P = 0.022), and performance of a repeat CRS plus HIPEC
after detection of recurrence (P = 0.03) (Table 3).
Other variables such as age, sex, area, time period of
CRS plus HIPEC, primary tumor site, synchronous PM,
neoadjuvant chemotherapy, adjuvant chemotherapy, and
delivery details of HIPEC were not found significantly
associated with OS after CRS plus HIPEC. Moreover, the
univariate analysis found absence of lymph node metasta-
sis (P = 0.029), normal value of CA19-9 before CRS plus
HIPEC (P = 0.001), absence of acites (P = 0.021), PCI of
15 or lower (P = 0.009), and absence of postoperative
complications (P = 0.001) to be associated significantly
with improved DFS after CCR 0 or 1.
TABLE 1 Characteristics of 152 patients with peritoneal metastases
(PM) from small bowel adenocarcinoma treated with cytoreductive
surgery (CRS) plus hyperthermic intraperitoneal chemotherapy
(HIPEC)
Characteristic Patients (n) %
Age (years)
B 60 113 74.3
[ 60 38 25.0
Unknown 1 0.7
Sex
Male 82 53.9
Female 70 46.1
Area
Western country 115 75.7
Asia 37 24.3
Time period of CRS?HIPEC
1989–2001 12 7.9
2001–2010 59 38.8
2011–2016 77 50.7
Unknown 4 2.6
Surgical resection of primary tumor before CRS?HIPEC
Yes 123 81
No 27 17.7
Unknown 2 1.3
Primary tumor site
Duodenum 10 6.6
Jejunum 86 56.6
Ileum 44 29.0
Unknown 12 7.8
Tumor differentiation
Well-differentiated 29 19
Moderately differentiated 72 47.4
Poorly differentiated 38 25
Unknown 13 8.6
Synchronous PC
Yes 96 63.2
No 51 33.5
Unknown 5 3.3
Lymph node metastasis
Yes 45 29.6
No 88 57.9
Unknown 19 12.5
Extraperitoneal metastasis
Yes 13 8.6
No 138 90.7
Unknown 1 0.7
Neoadjuvant chemotherapy before CRS?HIPEC
Yes 82 54.0
No 57 37.5
Unknown 13 8.5
TABLE 1 continued
Characteristic Patients (n) %
Presence of ascites
Yes 23 15.1
No 110 72.4
Unknown 19 12.5
Peritoneal cancer index
B 15 96 63.2
[ 15 40 26.3
Unknown 16 10.5
Completeness of cytoreduction
0 114 75
1 20 13.1
2 or 3 15 9.9
Unknown 3 2.0
Postoperative complication
No 85 55.9
Yes 60 39.5
Unknown 7 4.6
Adjuvant chemotherapy after CRS?HIPEC
Yes 81 53.3
No 46 30.2
Unknown 25 16.5
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A multivariate analysis with a Cox regression model
was performed to determine independent predictors of
improved OS after CRS plus HIPEC. An improved OS
after CRS plus HIPEC was predicted by an interval of
6 months or less between detection of PM and date of CRS
plus HIPEC [hazard ratio(HR) 0.180; 95% confidence
interval (CI) 0.089–0.697; P = 0.008], no lymph node
metastasis during CRS plus HIPEC (HR 0.315; 95% CI
0.138–0.941; P = 0.037), well-differentiated tumor (HR
0.052; 95% CI 0.020–0.801; P = 0.028), and a PCI of 15
or lower (HR 0.002; 95% CI 0.000–0.104; P = 0.003).
DISCUSSION
The survival of patients with advanced SBA is poor,
with a median overall 5-year survival rate of 3–5%.5,22 In
addition, a median survival of approximately 20 months is
reported for patients treated with oxaliplatin-based
chemotherapy.6,23
In the current study, SBA patients who had PM treated
with CRS plus HIPEC experienced a median OS of
32 months and a 5-year survival rate of 30.8%, reaching
the median OS obtained for patients who had colorectal
carcinomatosis treated with the same therapeutic strat-
egy.24 This promising result suggests that CRS plus HIPEC
may confer a promising survival benefit for patients with
PM from SBA. Moreover, an interval of 6 months or less
between detection of PM and date of CRS plus HIPEC is
recommended because it was identified as an independent
predictor for better OS in the current study.
Although details of the method for delivering HIPEC
varied among the institutions in this study, they were not
associated with OS. Oxaliplatin-based chemotherapy was
not identified as an independent variable, but showed a
significant survival advantage over the mitomycin C
(MMC)-based chemotherapy regimen in the univariable
analysis in this registry. In addition, considering the sur-
vival advantage of oxaliplatin-based chemotherapy over
other chemotherapy regimens demonstrated by other
studies,6–8 we suggest recommending an oxaliplatin-based
chemotherapy regimen for HIPEC for patients with PM
from SBA. However, it is worth noting that the numbers of
patients treated with various regimens precludes definitive
conclusions on the optimal agent in the perfusate.
In the current study, well-differentiated tumor, absence
of lymph node metastasis, and a PCI of 15 or lower were
independently associated with improved OS. These factors
also were demonstrated to have a favorable influence on
the survival of patients with SBA in other retrospective
studies.24–28 Patients with well-differentiated tumor had a
median OS of 54 months, which was significantly better
than the OS of patients with moderately or poorly differ-
entiated tumor.
Lymph node metastasis was frequent in SBA patients
with PM, at an incidence of 33% and even 48.3% during
the whole disease course in this study. The median OS after
CRS plus HIPEC was significantly better for the patients
without lymph node metastasis than for the patients with
lymph node metastasis (36 vs 18 months). Although severe
tumor burden also is usually demonstrated with strong
association to poorer survival for patients with PM,7–9 it
generally is difficult to obtain precise details of intraperi-
toneal tumor dissemination until CRS.
Recently, laparoscopic HIPEC has been used for precise
understanding and reduction of PCI before CRS in gastric
cancer.29 By performing laparoscopic HIPEC before CRS,
tumor dissemination can be directly understood, and PCI
can be significantly decreased at the same time. Therefore,
laparoscopic HIPEC can be considered with preoperative
systemic chemotherapy for PM from SBA.
In the registry of this study, the patients who received
CCR of 0 had a median OS of 43 months, which was
significantly better than the OS for patients who received
CCR 1–3 surgery (P\ 0.001).
The feasibility of achieving complete cytoreduction
depends mainly on tumor burden and technique expertise.
For patients with severe tumor burden, achieving a CCR of
0 may increase the risk of postoperative major complica-
tions. Postoperative complication was related to
postoperative OS and DFS. Although almost all the
patients had disease recurrence during the long-term fol-
low-up assessment, those selected to undergo a repeat CRS
plus HIPEC had better survival. However, only a minority
of the patients received a repeat CRS plus HIPEC. As a
result, an attempt should be made to avoid postoperative
TABLE 2 Chemotherapy agents used in hyperthermic intraperi-
toneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for
peritoneal metastases (PM) from small bowel adenocarcinoma (SBA)
Chemotherapy n
MMC regimens 73
MMC 58
MMC?cisplatin 7
MMC?doxorubicin 5
MMC?irinotecan 3
Oxaliplatin regimens 72
Oxaliplatin (± 5-FU/LV) 48
Oxaliplatin?irinotecan 24
Other regimens 7
Doxorubicin 1
Docetaxel?cisplatin 1
Doxorubicin?cisplatin 2
Docetaxel 3
MMC mitomycin C, 5-FU 5- fluorouracil
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complication during CRS plus HIPEC, and close follow-up
evaluation should be carried out after complete cytore-
duction to detect potentially resectable recurrence, thereby
maximizing the chance of repeat CRS and HIPEC.
Regarding neoadjuvant and adjuvant chemotherapy, no
significant difference in survival was shown in this registry.
However, systemic chemotherapy after detection of PM
may contribute to a decrease in the values of CA125 and
CA 19-9, which were significantly related to postoperative
OS. Similarly, the survival benefit of systemic
chemotherapy versus best supportive care alone has been
shown in several retrospective studies.22,23 Although the
rarity of SBA makes randomized trials impractical for
comparing the efficacy of chemotherapy regimens based on
the efficacy of the fluoropyrimidine-oxaliplatin-based
chemotherapy regimen reported in multicenter retrospec-
tive studies, neoadjuvant and adjuvant systemic
chemotherapy using the fluoropyrimidine-oxaliplatin-based
regimen can be considered as an option for patients with
PM from SBA.7,8 Moreover, the neoadjuvant course of
therapy would have to be limited so CRS and HIPEC can
be completed within 6 months after a PM diagnosis.
Aparicio et al.23 studied the molecular biology of SBA
and showed that defective mismatch repair (dMMR) phe-
notype and mutated KRAS status were significantly
associated with improved OS for all patients and for stage 4
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CumulativeFIG. 1 Overall survival after
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chemotherapy for patients with
peritoneal metastases from
small bowel adenocarcinoma
(n = 152)
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TABLE 3 Univariate analysis of overall survival after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
for patients with peritoneal metastases (PM) from small bowel adenocarcinoma (SBA)
Variable Median survival (months) 95% CI Log-rank P value
Age (years)
B 60 32 22.1–41.9 0.928
[ 60 30 22.0–38.0
Sex
Male 34 26.3–35.7 0.528
Female 30 18.0–50.0
Area
Western countries 30 21.6–38.4 0.404
Asia 36 19.3–52.7
Time period of CRS and HIPEC
1989–2000 42 2.93–87.1
2001–2010 25 19.2–28.8 0.066
2011–2016 – –
Resection of primary tumor
Yes 34 21.3–46.7 0.045
No 24 21.1–26.9
Primary tumor site
Duodenum 30 41.7–55.8 0.402
Jejunum 38 21.8–54.2
Ileum 28 15.7–40.3
Tumor differentiation
Well-differentiated tumor 54 1.6–106.4 0.037
Moderately differentiated tumor 32 19.5–44.5
Poorly differentiated tumor 24 17.3–30.7
Synchronous PC
Yes 30 21.2–38.8 0.333
No 36 20.9–51.1
Interval between detection of PM and CRS?HIPEC (months)
B 6 36 21.1–50.9 0.008
[ 6 14 5.8–22.2
Lymph node metastasis
Yes 18 10.6–25.4 \ 0.001
No 36 24.1–47.9
Extraperitoneal metastasis
Yes 20 10.3–29.7 0.030
No 32 18.8–45.2
Chemotherapy before CRS
Yes 30 20.1–39.9 0.742
No 30 18.3–41.7
Abnormal CA125
Yes 25 0–53.2 0.028
No 43 23.7–62.3
Abnormal CA 19-9
Yes 21 11.8–30.2 0.008
No 36 20.6–51.4
Presence of ascites
Yes 24 0–48.1 0.022
No 34 20.7–47.3
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patients, respectively. The progress in molecular charac-
terization and pathogenesis of SBA may have potential for
prospective development of novel targeted therapies.20
In conclusion, the large registry in this study demon-
strated that treatment using CRS plus HIPEC achieved
prolonged survival for selected patients with PM from SBA
and showed acceptable safety. Therefore, CRS plus HIPEC
should be considered as a new treatment option for selected
patients with PM from SBA. Based on the reported data, a
consensus statement by the Peritoneal Surface Oncology
Group International (PSOGI) with a clear recommendation
for a uniform HIPEC protocol for adenocarcinoma of the
small bowel should be published.
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